Mink Therapeutics Inc (INKT) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $11.03
• Market Cap: $53.84M
• EPS: $-3.01
• 52-Week High: $76.00
• 52-Week Low: $6.34

Market Sentiment

Mink Therapeutics Inc currently has a Neutral sentiment score of 0.14.

About Mink Therapeutics Inc

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical firm headquartered in New York, focused on the development of innovative allogeneic invariant natural killer T-cell therapies for cancer and immune-mediated diseases. By leveraging the unique capabilities of these immune cells, MiNK is advancing a promising therapeutic pipeline designed to provide next-generation treatment options in the rapidly evolving field of cell-based immunotherapies. The company's strategic emphasis on pione...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Mink Therapeutics Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does INKT pay dividends?

Mink Therapeutics Inc (INKT) does not currently pay a regular dividend.

What is INKT's market cap?

Mink Therapeutics Inc (INKT) has a market capitalization of $53.84M with a current stock price of $11.03.